Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC

Recruiting now

Conditions studied: Non-small Cell Lung Cancer

In brief

To investigate genomic architecture, cancer evolution and their relationship with clinical outcomes in EGFR-mutant NSCLC.

Key facts

Study ID

NCT05997719

Run by

Sun Yat-sen University

People needed

150

Starts

2023-08-10

Expected to finish

2030-12-31

Last updated by the study team

2023-10-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged 18 years or older
• Histologically or cytologically confirmed non-small-cell lung cancer
• ECOG PS=0-2
• EGFR mutations confirmed by tissue or peripheral blood
• Can provide tumor tissue samples (fresh or archived)
• The subject should have good compliance, who would participate in the research voluntarily, and sign the informed consent

You may not qualify if…

• History of other malignancies within 5 years (excluding basal cell carcinoma of the skin or other carcinoma in situ that has been resected).
• Unable to provide sufficient tumor tissue for analysis.
• Subjects with active, unstable systemic diseases, such as active infection, uncontrolled hypertension, heart failure (NYHA class >= II), unstable angina pectoris, acute coronary syndrome, severe arrythmia, severe liver, kidney or metabolic diseases, HIV infection.
• Subjects who are deemed unable to comply with the study requirements or complete the study.

Where it is running

• Sun Yat-sen University Cancer Center — Guanzhou, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.